RECRUITING

Diversity and Inclusion in Research Underpinning Prevention and Therapy Trials

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This proposal brings together multidisciplinary teams from four New York City institutions charged with reducing cancer disparities that affect approximately two million people residing in some of the most diverse and underserved communities in the United States. The intent of this collaborative research is captured by its acronym, DISRUPT: Diversity \& IncluSion in Research Underpinning Prevention \& Therapy Trials. To disrupt the norms that maintain heightened risk and poorer outcomes experienced by BIPOC, the research team propose three integrated and synergistic aims to improve diversity and inclusion in CTs through disruptive approaches at the community (Aim 1), provider, system and patient (Aim 2), and basic and translational scientist levels (Aim 3). All three aims focus on metrics for changing norms reified in institutional policies and established practice that will provide essential evidence to translate and scale these changes to institutions and networks involved in cancer treatment research. In Aim 1, the research team will partner with local organizations to formulate and disseminate new norms regarding cancer care and research and diffuse these new norms throughout the community via community organizations and Health Ambassadors bringing a different vantage point on CTs, raising awareness and increasing demand for access to cancer research. In Aim 2, the research team will create an electronic approach to identify key clinical characteristics of patients and trials and match patients and trials and bring these data to patients and their physicians at the time of key decisions. In Aim 3, the research team will provide and integrate essential experiential training in diversity, social determinants of health and the importance of conducting community-relevant work into basic and translational science training. This DISRUPT proposal provides the foundation to disrupt norms about cancer clinical trials in our communities, delivery systems and scientific research enterprises.

Official Title

Diversity and Inclusion in Research Underpinning Trials

Quick Facts

Study Start:2022-12-24
Study Completion:2025-04
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05146297

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:21 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * All patients \>21 years of age with invasive breast, lung or liver cancer, who face a treatment decision
  2. * patients of doctors who have consented to participate
  3. * able to give consent and speak either English or Spanish
  4. * For provider recruitment, oncologists, and advanced practitioners caring for patients with breast, lung, liver cancer including medical and surgical oncologists, interventional radiologists \& hepatologists will be eligible
  1. * Patients who are unable to give consent
  2. * unable to understand English or Spanish
  3. * lack of invasive breast/liver cancer
  4. * those who do not face an imminent treatment decision

Contacts and Locations

Study Contact

Radhi Yagnik
CONTACT
212-659-5933
radhi.yagnik@mountsinai.org

Principal Investigator

Nina Bickell
PRINCIPAL_INVESTIGATOR
Icahn School of Medicine at Mount Sinai

Study Locations (Sites)

Albert Einstein College of Medicine
Bronx, New York, 10461
United States
Icahn School of Medicine at Mount Sinai
New York, New York, 10029
United States
Herbert Irving Comprehensive Cancer Care Center
New York, New York, 10032
United States

Collaborators and Investigators

Sponsor: Icahn School of Medicine at Mount Sinai

  • Nina Bickell, PRINCIPAL_INVESTIGATOR, Icahn School of Medicine at Mount Sinai

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2022-12-24
Study Completion Date2025-04

Study Record Updates

Study Start Date2022-12-24
Study Completion Date2025-04

Terms related to this study

Additional Relevant MeSH Terms

  • Breast Cancer
  • Liver Cancer
  • Prostate Cancer